Paul Germonpre

Paul Germonpre

Gent, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Correction: WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.

Correction: WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.

Journal: Journal of hematology & oncology

Published: March 20, 2025

WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.

WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.

Journal: Journal of hematology & oncology

Published: August 26, 2024

Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.

Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.

Journal: PloS one

Published: February 19, 2024

The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies.

The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies.

Journal: Molecules (Basel, Switzerland)

Published: October 16, 2019

Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability.

Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability.

Journal: PloS one

Published: August 23, 2018

A Multicenter Study to Assess EGFR Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical Setting.

A Multicenter Study to Assess EGFR Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical Setting.

Journal: Cancers

Published: July 16, 2018

Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals.

Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 29, 2017

Inhaled treatment of COPD: a Delphi consensus statement.

Inhaled treatment of COPD: a Delphi consensus statement.

Journal: International journal of chronic obstructive pulmonary disease

Published: March 16, 2017

Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC.

Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC.

Journal: Clinical lung cancer

Published: March 14, 2017

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer.

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer.

Journal: World journal of clinical oncology

Published: June 20, 2016

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 04, 2014

ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.

ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.

Journal: Translational lung cancer research

Published: February 20, 2014

Showing 1-12 of 15

Last Updated: 09/26/2026